130 related articles for article (PubMed ID: 30036195)
1. Inherited gynaecological cancers.
George A
Curr Opin Oncol; 2018 Sep; 30(5):317-322. PubMed ID: 30036195
[TBL] [Abstract][Full Text] [Related]
2. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
3. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
4. Genetics of gynaecological cancers.
Constantinou P; Tischkowitz M
Best Pract Res Clin Obstet Gynaecol; 2017 Jul; 42():114-124. PubMed ID: 28202331
[TBL] [Abstract][Full Text] [Related]
5. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
6. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
7. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Kristeleit RS; Miller RE; Kohn EC
Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
[TBL] [Abstract][Full Text] [Related]
8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
9. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
Hoskins PJ; Gotlieb WH
CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
[TBL] [Abstract][Full Text] [Related]
10. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
11. Genetic predisposition in gynecologic cancers.
Daniels MS; Lu KH
Semin Oncol; 2016 Oct; 43(5):543-547. PubMed ID: 27899185
[TBL] [Abstract][Full Text] [Related]
12. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
14. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
15. Current and future role of genetic screening in gynecologic malignancies.
Ring KL; Garcia C; Thomas MH; Modesitt SC
Am J Obstet Gynecol; 2017 Nov; 217(5):512-521. PubMed ID: 28411145
[TBL] [Abstract][Full Text] [Related]
16. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
17. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
Tang YH; Lin CY; Lai CH
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
[TBL] [Abstract][Full Text] [Related]
18. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
19. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers.
Ueda T; Tsubamoto H; Takimoto Y; Isono-Taniguchi R; Narita S; Nakagawa K; Wakimoto YU; Nishimura Y; Muroi Y; Nagahashi M; Hirota S; Sawai H; Shibahara H
Anticancer Res; 2023 May; 43(5):2091-2101. PubMed ID: 37097652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]